Abstract-Preeclampsia, a major cause of maternal and perinatal mortality and morbidity, is thought to be attributed, in part, to impaired trophoblast invasion. Peroxisome proliferator-activated receptors are ligand-activated transcription factors expressed in trophoblasts, which regulate the expression of a number of genes involved in cell differentiation and proliferation. We investigated the effect of the administration of a peroxisome proliferator-activated receptor-␥ antagonist during uncomplicated pregnancy in rats. Using an intraperitoneal miniosmotic pump, healthy pregnant rats were administered either vehicle or the peroxisome proliferator-activated receptor-␥-specific antagonist, T0070907 (1 mg/kg per day from gestational days 11-15). Rats treated with T0070907 developed key features of preeclampsia, including elevated mean arterial blood pressure, proteinuria, endothelial dysfunction, reduced pup weight, and increased platelet aggregation. T0070907-treated rats had reduced plasma vascular endothelial growth factor and increased plasma soluble fms-like tyrosine kinase 1. Furthermore, increases in total placental soluble fms-like tyrosine kinase 1 mRNA and fms-like tyrosine kinase 1 protein were also demonstrated, suggesting the placenta as the main contributor to the increased circulating levels of soluble fms-like tyrosine kinase 1. The labyrinthine trophoblast in the placentas of T0070907-treated rats were less differentiated, had increased cellular proliferation, and were strongly immunopositive for CD-31 staining, indicating adaptive angiogenesis. The present study suggests that peroxisome proliferator-activated receptor-␥ may play a pivotal role in the progression of a healthy pregnancy and may critically regulate the risk of preeclampsia. These findings have important implications regarding the underlying etiology of preeclampsia and potential therapeutic targets. Key Words: peroxisome proliferator activated receptor-␥ Ⅲ T0070907 Ⅲ preeclampsia Ⅲ vascular dysfunction P reeclampsia is a major cause of maternal and perinatal mortality and morbidity worldwide causing Ϸ15% of all direct maternal deaths and mediating a 5-fold increase in perinatal mortality. 1 Although the underlying etiology of preeclampsia is poorly understood, this condition is characterized by a relatively hypoperfused placenta, which stimulates the maternal response manifesting as hypertension, vascular dysfunction, and a pro-oxidant state. 2 Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that regulate the expression of a number of genes involved in cell differentiation and proliferation. 3 PPAR-␥ plays a predominant role in normal vascular function 4,5 and in the differentiation of labyrinthine trophoblast lineages, 6 which, along with the fetal endothelium, form the vascular exchange interface with maternal blood. 7 Homozygous PPAR-␥-deficient embryos die because of placental dysfunction, 8 and PPAR-␥ null placentas develop a malformed labyrinth zone, 9 suggesting a critical role for PPAR-␥ in the progression of normal pregnancy. More recently, a role for PPAR-␥ in the pathogenesis of preeclampsia has been suggested, because administration of a PPAR-␥ agonist to a rodent model of preeclampsia ameliorated several of the hallmarks of this condition. 10 In addition, recent data have demonstrated that serum concentrations of endogenous agonists of PPAR-␥ are significantly reduced in women with severe early onset preeclampsia compared with healthy pregnant women. 11 In contrast, Holdsworth-Carson et al 12 demonstrated that placentas from women with preeclampsia did not exhibit any changes in either PPAR-␥ activity or placental expression of PPAR-␥ mRNA and PPAR-␥ protein, thus whether aberrant PPAR-␥ activity is involved in the development of pregnancies complicated by hypertension is not known. Furthermore, because of the limitations of conducting studies in pregnant women, and the embryonic lethality of homozygous PPAR-␥ receptor gene knockout in rodents, 9 the functional role of PPAR-␥ in normal pregnancy remains unclear. We hypothesized that the antagonism of PPAR-␥ would adversely affect the progression of normal rodent
P
reeclampsia is a major cause of maternal and perinatal mortality and morbidity worldwide causing Ϸ15% of all direct maternal deaths and mediating a 5-fold increase in perinatal mortality. 1 Although the underlying etiology of preeclampsia is poorly understood, this condition is characterized by a relatively hypoperfused placenta, which stimulates the maternal response manifesting as hypertension, vascular dysfunction, and a pro-oxidant state. 2 Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that regulate the expression of a number of genes involved in cell differentiation and proliferation. 3 PPAR-␥ plays a predominant role in normal vascular function 4, 5 and in the differentiation of labyrinthine trophoblast lineages, 6 which, along with the fetal endothelium, form the vascular exchange interface with maternal blood. 7 Homozygous PPAR-␥-deficient embryos die because of placental dysfunction, 8 and PPAR-␥ null placentas develop a malformed labyrinth zone, 9 suggesting a critical role for PPAR-␥ in the progression of normal pregnancy. More recently, a role for PPAR-␥ in the pathogenesis of preeclampsia has been suggested, because administration of a PPAR-␥ agonist to a rodent model of preeclampsia ameliorated several of the hallmarks of this condition. 10 In addition, recent data have demonstrated that serum concentrations of endogenous agonists of PPAR-␥ are significantly reduced in women with severe early onset preeclampsia compared with healthy pregnant women. 11 In contrast, Holdsworth-Carson et al 12 demonstrated that placentas from women with preeclampsia did not exhibit any changes in either PPAR-␥ activity or placental expression of PPAR-␥ mRNA and PPAR-␥ protein, thus whether aberrant PPAR-␥ activity is involved in the development of pregnancies complicated by hypertension is not known. Furthermore, because of the limitations of conducting studies in pregnant women, and the embryonic lethality of homozygous PPAR-␥ receptor gene knockout in rodents, 9 the functional role of PPAR-␥ in normal pregnancy remains unclear. We hypothesized that the antagonism of PPAR-␥ would adversely affect the progression of normal rodent pregnancy and lead to the development of several of the characteristic features of preeclampsia.
Materials and Methods

Animals
Sprague-Dawley timed pregnant rats were supplied and maintained by the University College Cork Biological Services Unit. Animals were maintained at a temperature of 21Ϯ2°C, with a 12-hour light/dark cycle and free access to food and tap water. All of the procedures were performed in accordance with national guidelines and the European Community Directive 86/609/EC and approved by the University College Cork Local Animal Experimentation Ethics Committee (2009/04).
PPAR-␥ Antagonist In Vivo Experimental Protocol
PPAR-␥ antagonism during pregnancy was investigated in a series of experiments via the administration of either T0070907 (1 mg/kg per day; Cayman Chemical), 13 a PPAR-␥ antagonist, or vehicle (40% dimethylsulphoxide solution) over a 5-day period (gestational days [GDs] 11-15) using an intraperitoneal miniosmotic pump (ALZET 2ML1). Under anesthesia with isoflurane (2% to 5% inhalation), on GD11, a laparotomy incision was made, pup number noted, pump inserted, and the animal allowed to recover. On GD18, animals were anesthetized with isoflurane, a chronic indwelling catheter (0.58 mm ID ϫ 0.99 mm OD) inserted into the carotid artery, which was exteriorized at the back of the neck and animals allowed to recover before conscious mean arterial blood pressure measurement on GD19. After completion of mean arterial blood pressure measurements, animals were anesthetized with isoflurane, blood collected via the abdominal aorta into precooled heparinized vacutainers, and the mesenteric arterial arcade excised and placed in ice-cold physiological salt solution. All of the pups and placentas were removed, weighed, and litter size noted. The concentration of T0070907 used in this study was chosen on the basis of a previously published study. 14, 15 
Isometric Myography
After culling of the rat, third-order mesenteric arteries were dissected out within 1 hour and mounted onto a 4-channel wire myograph (model 610 mol/L, Danish Myo Technology, Aarhus, Denmark) containing oxygenated (95% O 2 and 5% CO 2 ) physiological salt solution at 37°C. Vessels were normalized to achieve a transmural pressure of 100 mm Hg using the Danish Myo Technology Normalization software. Isometric tension was recorded and displayed using Powerlab and Chart Software (both AD Instruments). The viability of the smooth muscle was tested via the addition of a 123-mmol/L KCl solution. After 2 physiological salt solution washes, cumulative concentration responses were carried out with the thromboxane mimetic, U46619 (9,11-dideoxy-11␣,9␣-epoxymethanoprostaglandin F 2␣ ; 10 Ϫ9 to 3ϫ10 Ϫ7 mol/L), and either bradykinin (10 Ϫ9 to 10 Ϫ5 mol/L) or sodium nitroprusside (10 Ϫ9 to 10 Ϫ5 mol/L). U46619 induced a concentration-dependent increase in active wall tension in all of the groups, but the maximum contraction to the vasoconstrictor did not differ significantly between groups.
Platelet Aggregation Studies
Ex vivo platelet aggregation studies were performed in response to either adenosine diphosphate (ADP) or collagen (for extended method please see the online Data Supplement at http://hyper.ahajournals.org).
Urine Analysis
On GD18, each rat was singularly housed in a metabolic cage and urine collected overnight for analysis of microalbumin:creatinine ratios (for extended method please see the online Data Supplement).
Plasma Induced Alterations in Vascular Function
Previously we have demonstrated that treatment of mesenteric vessels from normal pregnant rats with plasma from the reduced uterine perfusion pressure (RUPP) rat (a rodent model of preeclampsia) induces endothelial dysfunction. 16 To investigate whether plasma from PPAR-␥ antagonist-treated rats behaved similarly to RUPP plasma, in terms of adversely affecting vascular function in mesenteric vessels from normal pregnant rats, we performed a separate series of experiments in which vessels were incubated overnight in plasma and their vascular function assessed. For plasma preparation, whole blood was collected as described previously and centrifuged at 2400g for 10 minutes at 4°C, the plasma removed and stored in 250-L aliquots at Ϫ80°C. Pregnant rats (GD19) were euthanized via CO 2 asphyxiation and third-order mesenteric arteries dissected out and incubated overnight at 4°C in 3% plasma from rats treated with either vehicle or T0070907. This plasma concentration was chosen because an equivalent concentration of RUPP plasma was shown previously to induce endothelial dysfunction in mesenteric vessels. 16 After overnight incubation, vessels were mounted onto a wire myograph and vascular function assessed as described previously.
Measurement of Angiogenic Mediators via ELISAs
Blood was collected as described above. Circulating soluble fms-like tyrosine kinase (sFlt) 1, vascular endothelial growth factor (VEGF), heme oxygenase 1 (HO-1), and interleukin 6 levels were measured in plasma samples using commercial ELISA kits available from R&D Systems (sFlt-1, VEGF, and interleukin 6; Quantikine) and Enzo Life Sciences (HO-1) according to the manufacturer's directions.
Histological Analysis
Kidneys and placentas were removed from rats and fixed in 4% formal buffered saline for 48 hours. Samples were processed (Tissue Tek VIP 5JR, Syntec Scientific Ltd, Dublin, Ireland), embedded in paraffin wax, and 4-m serial sections cut, which were subsequently stained with hematoxylin and eosin.
Immunohistochemistry for sFlt-1, HO-1, CD-31, and Ki-67
Paraffin-embedded placental sections (4 m) were incubated with the following primary antibodies used at the following dilutions: sFlt-1, 1:400 (Abcam ab2350); HO-1, 1:100 (Abcam ab13248); Ki-67, 1:100 (LabVision RM-9106-S), and CD-31, 1:100 (Abcam ab28364). Rate of proliferation was assessed by blindly counting the percentage of Ki-67 immunopositive cells in randomly generated images from the placental labyrinths of all placentas (for extended method please see the online Data Supplement).
Quantitative RT-PCR
Total RNA was extracted from snap-frozen placental tissue and PCR performed with specific primers for sFlt-1 (forward primer 5Ј-ACG TCA CAG ATG TGC CAA AC-3Ј; reverse primer 5Ј-CAA CAC AGG ACA GTT TCA GG-3Ј), HO-1 (forward primer 5Ј-ACG TCA CAG ATG TGC CAA AC-3Ј; reverse primer 5Ј CTG AAA GTT CCT CAT GAA CTC-3Ј), and PPAR-␥ (forward primer 5Ј-GTC TCA CAA TGC CAT CAG GT-3Ј; reverse primer 5Ј-GTT CAG CTG GTC GAT ATC AC-3Ј). Levels of mRNA expression were calculated using the mathematical formula for ⌬/⌬cycle threshold and gene expression normalized to the geometric means of 2 housekeeping genes (insulin-like growth factor receptor 1 and platelet-derived growth factor A). Analysis was carried out using CFX Manager Software and data expressed as fold changes relative to controls (for extended methods please see the online Data Supplement).
Statistical Analysis
All of the calculations were performed on data from GD19 animals. Concentration-response curves for all vascular data were generated using GraphPad Prism. Concentration responses between groups were compared via repeated-measures ANOVA and Bonferroni post hoc test. Both EC 50 values (expressed as Ϫlog[mol/L]ϮSEM) and R max values (maximal relaxation as a percentage of induced tone) were compared using a 2 tailed t test. For all of the other data, either a 2 tailed t test or Mann-Whitney test was used to determine significance. For all of the experimental groups, data were expressed as the meanϮSEM, and significance was determined as PϽ0.05.
Solutions and Chemicals
All of the chemicals were purchased from Sigma-Aldrich (Dorset, United Kingdom) unless otherwise stated.
Results
After administration of T0070907, healthy pregnant rats developed elevated mean arterial blood pressure compared with the control group (116Ϯ3 versus 106Ϯ3 mm Hg; PϽ0.05; nϭ8 -9; Figure 1 ). PPAR-␥ antagonist-treated rats demonstrated reduced pup weight (2.9Ϯ0.2 versus 3.9Ϯ0.4 g; Pϭ0.057; nϭ7-9; Figure S1A , available in the online Data Supplement) and increased placental weights (0.54Ϯ0.02 versus 0.45Ϯ0.01 g; PϽ0.001; nϭ8; Figure S1B ) compared with the control group. No differences were observed in pup number between the control and treatment groups (14Ϯ1 versus 11Ϯ2 g; P value not significant; nϭ8 -10; Figure S1C ).
Mesenteric arteries from T0070907-treated rats displayed impaired relaxation in response to bradykinin (R max : 56Ϯ4% versus 74Ϯ3%; PϽ0.01; log EC 50Ϫ : 8.32Ϯ0.08 versus Ϫ8.42Ϯ0.07 mol/L; PϽ0.001; Figure 2 ) compared with controls. No differences were observed between groups in response to sodium nitroprusside ( Figure S2 ), suggesting that the vascular dysfunction observed was because of adverse changes in the endothelium rather than the smooth muscle, a mechanism central to the pathogenesis of preeclampsia. 17 T0070907-treated rats had elevated microalbumin:creatinine ratios (24Ϯ4 versus 14Ϯ4 mg/mmol of creatinine; PϽ0.05; nϭ7-10; Figure 3 ) indicating proteinuria. However, histological examination of kidneys from these animals did not reveal any major structural abnormalities consistent with preeclampsia. PPAR-␥ antagonist administration resulted in increased ADP-induced platelet aggregation compared with control rats (28.4Ϯ5.0 versus 16.3Ϯ2.8 area under the curve; PϽ0.05; nϭ8 -9; Figure 4 ). In contrast, no difference was detected between groups in collagen-induced platelet aggregation (4.0Ϯ1.6 versus 3.8Ϯ2.5 area under the curve; Pϭ0.94; nϭ8 -9; Figure S3 ).
Pregnant rats administered T0070907 had reduced plasma VEGF (193.6Ϯ21.2 versus 399.5Ϯ33.2 pg/mL; PϽ0.001; nϭ8 -9; Figure 5 ) and increased plasma sFlt-1 (3485Ϯ306 versus 1851Ϯ782 pg/mL; PϽ0.05; nϭ7-10; Figure 6 ). Increases in total placental sFlt-1 mRNA (quantitative RT-PCR; PϽ0.05; nϭ7-10; Figure S4 ) and Flt-1 protein (immunohistochemistry; Figure S5A and S5B) were also demonstrated, suggesting the placenta as one of the main contributors to the increased circulating levels of sFlt-1. T0070907-treated rats had significantly elevated plasma HO-1 levels compared with vehicle-treated rats (172Ϯ35 versus 96Ϯ3 pg/mL; PϽ0.01; nϭ6 -8; Figure 7) . PϽ0.05; nϭ7-10; Figure S6 ) and protein (immunohistochemistry; Figure S7A and S7B) levels were elevated by Ͼ50% (mRNA) in T0070907-treated rats compared with controls. Plasma levels of the proinflammatory cytokine, interleukin 6, did not differ significantly between both control and PPAR-␥ antagonist-treated rats (96Ϯ4 versus 96Ϯ2 pg/mL; Pϭ0.91; nϭ8; Figure S8 ). Placental PPAR-␥ mRNA was reduced by Ϸ30% in T0070907-treated rats compared with vehicle-treated rats (0.68Ϯ0.11 versus 1.00Ϯ0.14; PϽ0.05; nϭ7; Figure 8 ).
Histological examination of placentas demonstrated that control rat placentas had a very thin trophospongium layer consistent with a mature well-differentiated placenta ( Figure  S9A ). 18 In contrast, the labyrinthine trophoblast in the placentas of PPAR-␥ antagonist-treated rats retained a prominent trophospongium (less differentiated trophoblast; Figure  S9B ), normally seen at GD15, indicating restricted placental development. A significant increase in Ki-67-positive cells was detected in the labyrinths of placentas from PPAR-␥ antagonist-treated rats (13.0Ϯ0.7% versus 7.0Ϯ0.2% total cells; PϽ0.05; nϭ6 -7; Figure S10 ), indicating increased cellular proliferation compared with controls ( Figure S11A and S11B). Minimal staining for CD-31 (an indicator of vascularity) was observed in placental tissue from control rats ( Figure S12A ). In contrast, enhanced CD-31 immunoreactivity was observed in placentas from T0070907-treated rats ( Figure S12B ), indicating adaptive angiogenesis.
Overnight incubation of mesenteric vessels from healthy pregnant rats with plasma obtained from PPAR-␥ antagonisttreated rats resulted in impaired vasorelaxation to bradykinin compared with those incubated with plasma from vehicletreated rats (R max 50Ϯ8% versus 88Ϯ4%; PϽ0.01; Figure 9 ). In further support of a role for the endothelium in mediating this vascular dysfunction, concentration-response curves to the endothelial-independent vasodilator, sodium nitroprusside, did not differ between groups ( Figure S13 ).
Discussion
Accumulating evidence supports a role for PPAR-␥ in both placental development and embryogenesis, because studies involving the ablation of the PPAR-␥ gene in mice demonstrated a disruption in both the terminal differentiation of the labyrinthine trophoblast and placental vascularization. In the present study, administration of a PPAR-␥ antagonist to pregnant rats resulted in the development of elevated blood pressure, endothelial dysfunction, proteinuria, and an imbalance of angiogenic proteins, all classic hallmarks of preeclampsia. These manifestations may have occurred, at least in part, in response to alterations in trophoblast differentiation, because the placentas of T0070907-treated rats were characterized by immature trophospongium development and an increased rate of cell proliferation.
In preeclampsia there is extensive platelet activation and increased adhesion to vascular endothelial cells. 19 Activated platelets act as a major source of reactive oxygen species and may contribute considerably to the oxidative stress associated with preeclampsia. PPAR-␥ antagonist administration resulted in increased ADP-induced platelet aggregation compared with control rats, which may have occurred as a result of T0070907-mediated inhibition of eicosanoids, which are Preeclampsia is characterized by an imbalance of proangiogenic and antiangiogenic factors. 21 PPAR-␥ antagonisttreated rats displayed significantly reduced plasma levels of VEGF and significantly elevated levels of sFlt-1 compared with vehicle-treated rats, which would promote an antiangiogenic state. sFlt-1 is believed to be a significant contributor to endothelial damage in preeclampsia through interference with VEGF signaling. 22 Exogenous administration of sFlt-1 to pregnant rats has been shown previously to result in increased arterial blood pressure, proteinuria, glomerular endotheliosis, and associated decreases in plasma-free VEGF and placental growth factor (PLGF) concentrations. 21 These effects also occurred in nonpregnant rats, suggesting that sFlt-1 has a direct effect on the maternal endothelium, and it is likely the increased sFlt-1 levels observed after T0070907 administration contributed significantly to the elevated blood pressure and endothelial dysfunction described. Similarly, overnight incubation of mesenteric vessels from healthy pregnant rats with plasma obtained from PPAR-␥ antagonist-treated rats also resulted in impaired vasorelaxation to bradykinin, and it is possible that elevated circulating plasma sFlt-1 may have contributed in part to this endothelial dysfunction. Increases in total placental sFlt-1 mRNA and Flt-1 protein were also demonstrated, which may suggest that the placenta is one of the main contributors to the increased circulating levels of sFlt-1.
HO-1 is involved in regulating vascular tone, initiating anti-inflammatory responses, and reducing oxidative stress and tissue damage. It has been demonstrated that induction of HO-1 ameliorated hypertension and caused a significant shift in the angiostatic balance ratio (sFlt-1:VEGF) in rats subjected to a reduction in uterine perfusion pressure. 23 It was also demonstrated previously that PPAR-␥ ligands increased HO-1 expression in both smooth muscle and endothelial cells. 24 In contrast, with these data, in the present study, after PPAR-␥ antagonist administration, plasma HO-1 and placental HO-1 mRNA and protein levels were significantly elevated. Although previous studies have demonstrated the downregulation of HO-1 in preeclampsia, 25 it is possible that the upregulation of placental HO-1 observed here may have occurred as a protective anti-inflammatory response 26 supported by the finding that plasma levels of the proinflammatory cytokine, interleukin 6 (which has been shown previously to be elevated in RUPP rats 27 ), did not differ between groups. It is also possible that PPAR-␥ antagonism may differentially affect HO-1 expression in different tissues/cell types, that is, trophoblast tissue compared with smooth muscle and endothelial cells. 24 Although no other studies have replicated our experimental protocol, data from first-trimester PPAR-␥ studies are not entirely consistent with our findings. In general, these studies have investigated the use of activation of PPAR-␥ in the first trimester using rosiglitazone, a PPAR-␥ agonist. The use of rosiglitazone in these studies has been shown to inhibit the trophoblastic invasion process 28 and, in particular, to inhibit extravillous cytotrophoblasts invasion and impair early human trophoblast migration. 29 In contrast, PPAR-␥ antagonists were shown to promote extravillous cytotrophoblast cell invasion. 30 However, results from other studies are more consistent with our findings. Parast et al 7 demonstrated defects in both proliferation and differentiation in PPAR-␥ null trophoblast mouse stem cells. Barak et al 9 demonstrated that the labyrinthine trophoblasts in PPAR-␥ null mouse placentas failed to properly differentiate. Our data have also demonstrated an impairment in placental differentiation in PPAR-␥ antagonist-treated rats. These conflicting results are possibly a result of differing time points for pharmacological and genetic manipulation, differing antagonists, and species variation. Further complementary work is required using additional PPAR-␥ antagonists and alternative doses and times of PPAR-␥ inhibition to establish whether dose-and time-dependent effects occur and to help clarify the exact role that PPAR-␥ plays in the progression of normal pregnancy in each species at all of the time points.
PPAR-␥ antagonist-treated rats were characterized by restricted placental development, as evidenced by the presence of a prominent trophospongium (less differentiated trophoblast), which is normally present at GD15, although control rat placentas had a very thin trophospongium layer consistent with a mature well-differentiated placenta. 18 A significant increase in Ki-67-positive cells was also detected in the labyrinths of placentas from T0070907-treated rats, indicating increased cellular proliferation. These findings are analogous to data that showed defects in differentiation in PPAR-␥ null trophoblast stem cells. 7 CD-31 immunoreactivity was enhanced in placentas from T0070907-treated rats indicating adaptive angiogenesis, which may be secondary to the upregulation of placental HO-1, increasing the production of carbon monoxide, a vasodilatory smooth muscle relaxing agent with potent proangiogenic properties. 31 
Perspectives
The development of a preeclamptic-like phenotype, after administration of a PPAR-␥ antagonist, provides strong experimental support for our working hypothesis that PPAR-␥ critically regulates the risk of preeclampsia and, similarly, that an aberration in PPAR-␥ function adversely affects the progression of healthy pregnancy. These data 
